Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Postmenopausal Hormone Therapy & Hearing Loss Risk

Menopause; ePub 2017 May 8; Curhan, et al

Older age at menopause and longer duration of postmenopausal hormone therapy (HT) are associated with higher risk of hearing loss, according to a recent study. The prospective cohort study included 80,972 women in the Nurses’ Health Study (baseline age 27 to 44 years), who were followed from 1991 to 2013. Researchers found:

  • 18,558 cases of hearing loss were reported after 1,410,928 person-years of follow-up.
  • Older age at natural menopause was associated with higher risk of hearing loss.
  • Among postmenopausal women, oral HT was associated with higher risk of hearing loss and longer duration of use was associated with higher risk, compared with women who never used HT.

Citation:

Curhan SG, Eliassen AH, Eavey RD, Wang M, Lin BM, Curhan GC. Menopause and postmenopausal hormone therapy and risk of hearing loss. [Published online ahead of print May 8, 2017]. Menopause. doi:10.1097/GME.0000000000000878.